Table 2.

Main results of references about AIDs and lymphoma.

Subjects	Proportion of AIDs	Clinical features	Prognosis	References
612 DLBCL	17.3%	Thyroid disease dominated followed by RA. The proportion of AIDs was significantly higher in females.	Patients with AIDs primarily mediated by B-cell responses had a worse OS.	Morth et al., 2019 (4)
736 DLBCL, 703 FL, 302 MZL, 193 MCL, 297 HL, and 186 T-cell lymphoma	12.2% in DLBCL	RA was the most common autoimmune condition and was the highest in MZL (7.6%), followed by DLBCL (7.2%).	Patients with AIDs primarily mediated by B-cell responses had an inferior EFS in MCL and HL.	Kleinstern et al., 2018 (29)
435 B-NHL	22.5% in DLBCL	Time to relapse for all B-NHL patients with AIDs was significantly shorter than patients without AIDs, specifically in patients with DLBCL.	A history of B-cell-mediated AIDs was associated with shorter PFS and OS.	Kleinstern et al., 2018 (30)
1,771 DLBCL, 1,760 MM, 1,580 CLL, 936 MZL, and 787 FL	6.3% in DLBCL	Significantly increased risks for DLBCL and MZL were found for those with rheumatological disorders; the site distribution of those with/without rheumatological conditions.	The 1- and 3-year OS rates of patients with three or more preceding rheumatology episodes were 59.5% and 46.6%, respectively, which were significantly poorer than those of patients without rheumatology episodes in DLBCL.	Kane et al., 2019 (3)

ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; DLBCL-NOS, diffuse large B-cell lymphoma, not otherwise specified; EBV⁺ DLBCL, Epstein–Barr virus-positive diffuse large B-cell lymphoma; PCDLBCL-LT, primary cutaneous diffuse large B-cell lymphoma, leg type; DEL, double expressor lymphoma; GCB, germinal center B-cell-like; ABC, activated B-cell-like; UN, unclassified; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; AIDs, autoimmune diseases; RA, rheumatoid arthritis; EFS, event-free survival; OS, overall survival; FL, follicular lymphoma; MZL, marginal zone lymphoma; MCL, mantle cell lymphoma; HL, Hodgkin lymphoma; B-NHL, B-cell non-Hodgkin lymphoma; MM, multiple myeloma; CLL, chronic lymphocytic leukemia.